Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy

Job F.M. van Boven1,2, Federico Lavorini3, P.N. Richard Dekhuijzen4, Francesco Blasi5, David B. Price6,7 and Giovanni Viegi8,9

Affiliations: 1Dept of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2Dept of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3Dept of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 4Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. 5Dept of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. 6Academic Primary Care, University of Aberdeen, Aberdeen, UK. 7Observational and Pragmatic Research Institute, Singapore. 8Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy. 9CNR Institute of Biomedicine and Molecular Immunology, Palermo, Italy.

Correspondence: Job F.M. van Boven, Dept of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. E-mail: j.f.m.van.boven@rug.nl

@ERSpublications
Huge impact, but little attention: time to put respiratory non-adherence higher on Europe’s policy agenda! http://ow.ly/vVDj309Yblz

Cite this article as: van Boven JFM, Lavorini F, Dekhuijzen PNR, et al. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. Eur Respir J 2017; 49: 1700076 [https://doi.org/10.1183/13993003.00076-2017].

Introduction
"Drugs don’t work in patients that don’t take them" are the by now almost legendary words of former US Surgeon General C. Everett Koop. Arguably worse than “just not working”, for the European Union (EU), it has been estimated that non-adherence to medication is associated with almost 200 000 deaths and an excess cost of EUR80–125 billion [1]. Realising that 1) non-adherence affects about 50% of chronic medication users [2], of which the large majority elderly, and 2) tackling non-adherence requires a joint effort, the Senior International Health Association took the initiative to bring together seniors, clinical and adherence experts, and European Parliament members. On November 18 and 19, 2016, all these key stakeholders met at the First European Congress on Adherence to Therapy in Rimini, Italy, passionately chaired by Giovanni La Via, President of the Environment, Public Health and Food Safety Committee of the European Parliament. Notably, there were representatives from several major European scientific societies, i.e. those of pulmonology (ERS), atherosclerosis (EAS), urology (EAU), heart rhythm (EHRA), psychiatry (EPA), cardiology (ESC) and hypertension (ESH). The overall goal of the congress was to

Received: Jan 13 2017 | Accepted after revision: Jan 25 2017

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2017

identify unmet needs in adherence research, funding and policy by specifying the roles of patients, healthcare providers, societies, funding bodies and governments. In this report, we present the main conclusions and recommendations following the congress, in particular those of interest for healthcare policy regarding inhaled medication non-adherence in patients with obstructive airway diseases (i.e. asthma and/or chronic obstructive pulmonary disease (COPD)).

Clinical and economic impact of non-adherence to inhaled respiratory medication
For most chronic oral medications, prescribers’ recommendations usually indicate taking the correct dose at the right time of day. A complicating factor for inhaled respiratory medication is that the correct way of administration (i.e. proper inhaler handling and technique) is also of paramount importance, resulting in even lower real-world adherence rates compared to other chronic medications [3]. Despite continuous inhaler redesign and refinement [4], incorrect inhalation handling and techniques persist [5], resulting in suboptimal medication implementation and compromised asthma and COPD treatment outcomes [6]. The large number of inhalers currently available, as well as insurance policy-driven inhaler switching, may worsen these outcomes even more [7]. Furthermore, the use of multiple inhaler devices by an individual patient has been shown to be associated with a higher prevalence of errors than the use of single devices [8].

Exact inhaled respiratory medication adherence rates vary depending on the definition used, but are known to be lower in adolescents and certain other groups, such as those with lower socioeconomic status [9]. Non-adherence to inhaled medication, including inappropriate inhaler use, is associated with a higher mortality, increased number of exacerbations, hospitalisations and emergency department visits, as well as increased economic burden [10–13]. Obviously, both on the clinical and economic level, there is much to gain by focusing on solutions to enhance medication adherence in patients with obstructive airway diseases. In the EU, 600 000 people die each year because of respiratory diseases, up to one-fifth of the population aged 5–80 years will develop asthma, and prevalence and burden continue to rise [14].

Now that most of the background and consequences of non-adherence to inhaled medication are known, it seems time to really make some changes and, in our view, optimal implementation of adherence-enhancing interventions is currently the key. However, this requires a coordinated approach and adequate funding. The EU seems well equipped to fulfil this role. The question arises: what role has the EU played so far and what role should it play?

EU-funded projects related to adherence to inhaled respiratory medication
To enable adherence research, the availability of sufficient resources is a first prerequisite. Second, given the causes of non-adherence are multifactorial and complex [15], research could benefit from international, multidisciplinary and private–public collaboration. The EU could therefore play a key role in coordinating adherence research. Indeed, within the 7th Framework Programme (FP7) and Horizon 2020 frameworks, the EU has the possibility to stimulate collaborative research across Europe. In recent years, one of the most prominent adherence projects funded by the EU was the Ascertain Barriers for Compliance (ABC) project. This project has led to general, disease-neutral adherence recommendations at the policy, healthcare professional, patient and government level [16]. Within the ABC project, a new taxonomy to define adherence phases was established, now distinguishing between initiation, implementation and persistence [17]. In a later follow-up study focusing on respiratory medicine, special attention was paid to inhaler technique as an important part of the implementation phase [18]. Currently, two other EU-FP7-funded projects target some respiratory non-adherence issues, in particular related to asthma treatment. These are the EARIP and the ASTRO-LAB projects. EARIP aims to identify areas that scientists and funders should focus on regarding the optimisation of asthma treatment, including non-adherence issues [19]. ASTRO-LAB focuses on the use of long-acting β-agonists in asthma and also addresses adherence factors influencing pulmonary drugs’ effectiveness [20, 21]. However, none of these EU projects has a key focus on inhaler misuse and adherence-enhancing solutions, especially not in patients with COPD.

For the period 2014–2020, almost EUR75 billion is available [22] and more than 11 000 signed projects are currently funded through the EU Horizon 2020 programme [23]. About 30 grants have the word “adherence” in their primary project objective, of which only one focuses on adherence in asthma patients (ASTHMAPOC) and one on cystic fibrosis (MyCyFAPP). The number of large international projects focusing on non-adherence in general and in respiratory medicine seems, however, to fall short compared to the considerable clinical and economic impact of the issue. Back in 2005, a systematic review on adherence-enhancing interventions already noted that “improving adherence seems to be fairly low on the policy agenda, but better use of existing technologies (e.g. drug therapy) is likely to be more cost-effective than many new technologies”, later confirmed for COPD [24, 25]. Nevertheless, subsequent epidemiological studies on respiratory medication adherence continued to indicate consistently low adherence, and a very recent study
also showed hardly any improvements in inhaler technique over the last 30 years [4, 5], illustrating the need for better implementation strategies focusing on proper inhaled respiratory medication use.

Various solutions to tackle non-adherence in obstructive airway diseases
When designing and implementing interventions to tackle non-adherence in obstructive airway diseases, it is of utmost importance that one takes into account the multifactorial causes of non-adherence and tailor solutions accordingly. Much groundwork has already been performed, and we have now arrived at a stage where most of the underlying mechanisms, “phenotypes of non-adherence” and targets have been uncovered. The 2003 World Health Organization adherence report distinguished between erratic non-adherence (forgetfulness), intelligent non-adherence (conscious decision not to take medication due to side-effects or lack of beliefs, for example) and unwitting non-adherence (lack of knowledge) [2]. Given these different “phenotypes” (which can occur alongside each other), one-size-fits-all solutions are very likely to fail, and interventions should clearly be tailored to the specific needs and beliefs of each individual patient [26–28]. However, it is not only the patient that could be targeted when aiming to optimise adherence. Non-adherence modifiers at the patient, system and treatment level [11] could all play a role and are often the underlying cause of different types of non-adherence in one or more phases of the medication adherence process (figure 1). For adherence-enhancing interventions to work, healthcare providers must first make sure that they reaffirm the asthma/COPD diagnosis, treat comorbidities and urge patients to avoid triggers. Subsequently, it is necessary to 1) identify the phenotype of non-adherence and 2) find a tailored solution that fits the type of non-adherence and targets its underlying cause(s) appropriately. At the First European Congress on Adherence to Therapy, several potential solutions were identified and discussed, and these are summarised in figure 1. Most interventions have been described in the literature and are ready to be implemented in real-world practice, especially as some newly developed objective electronic adherence measurement techniques are becoming available [29, 30].

Key points from the First European Congress on Adherence to Therapy
During the First European Congress on Adherence to Therapy, lectures from European policy-makers, interactive public sessions and clinically oriented round-table discussions have resulted in a set of key recommendations to address the non-adherence issue within the EU. A general manifest was created in which adherence was positioned as a right for every patient and as an issue that requires increased awareness from all stakeholders involved [31]. In addition, issues of particular interest for the respective chronic disease areas represented were identified. In table 1 a summary of these general as well as respiratory-specific

![FIGURE 1 Targets for interventions to optimise adherence to inhaled respiratory medications. Rx: prescription.](https://doi.org/10.1183/13993003.00076-2017)
recommendations is provided. Both aspects may be of interest for future European funding calls and policy-making.

Conclusions
Despite the considerable clinical and economic burden of non-adherence, strategies to improve adherence in obstructive airway diseases have received too little attention. Taking into account the ageing European population, the increasing number of asthma/COPD patients and the wealth of new inhalers available, it is time to put non-adherence to inhaled respiratory medication higher on the policy agenda of European and national funding bodies.

Acknowledgements
The authors thank Stefano Nardini (Pulmonary and TB Unit, Vittorio Veneto General Hospital, Vittorio Veneto, Italy) for moderating the respiratory session and all discussants for their input. A full report from the First European Congress on Adherence to Therapy is available (www.seniorinternationalhealthassociation.org/events/european-congress-on-adherence-to-therapy/). The views and opinions expressed here are those of the authors only.

References


